
AcuraStem: A fast-growing startup innovating in precision medicine since 2016.
AcuraStem, founded in 2016, is a patient-based biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly sporadic ALS and FTD. The company's core mission revolves around its proprietary disease-modeling platform, iNeuroRx®, which aims to revolutionize drug discovery for these conditions. AcuraStem's approach emphasizes patient-focused research to overcome the limitations of traditional animal models in drug development.
The company's iNeuroRx® platform is recognized as a best-in-class tool for discovering novel, effective, and broadly-acting treatments. AcuraStem's work addresses a critical gap in the pharmaceutical industry, where drug failures in clinical trials often stem from an overreliance on animal models. By prioritizing patient-based research, AcuraStem strives to improve the understanding of neurodegenerative diseases and increase the success rate of drug development in this challenging field.

CuraSen Therapeutics
curasen.com

NeuroX1
neurox1.com

Accera

Aspen Neuroscience

APstem Therapeutics
apstemtx.com

Acelot
acelot.com

AlphaStem
alpha-stim.com

AxoSim
axosim.com

Stem Pharm
stempharm.com

Amylyx Pharmaceuticals
amylyx.com

AivoCode
aivocode.com

Adrx
adrxpharma.com

Cellaria
cellariabio.com

Herophilus
herophilus.com

Aracari Biosciences
Companies similar to AcuraStem include CuraSen Therapeutics, NeuroX1, Accera and Aspen Neuroscience.
AcuraStem was founded in 2016.
AcuraStem's headquarters is located in Monrovia, CA, US.
AcuraStem's most recent funding round was for $7M (USD) in January 2024.
As of Jan 30, 2024, AcuraStem has raised a total of $12M (USD).
AcuraStem has 36 employees as of Feb 5, 2024.